Company intelligence / Profile preview

Artisan Therapeutics

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

In a Phase 2a pilot study of the lead candidate ART-501, 4 out of 6 adult participants with Autism Spectrum Disorder (ASD) showed meaningful signs of clinical benefit. Improvements were noted in behavioral symptoms, including irritability and social withdrawal, as measured by the Aberrant Behavior Checklist (ABC-2). The treatment was reported to be well-tolerated with no serious adverse events.

Therapeutic areas: Psychiatry
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

ARD-501

Partnerships

Tulex Pharmaceuticals

Beyond the preview

Go deeper on Artisan Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Artisan Therapeutics.

Explore the full profile